NRX Pharmaceuticals (NRXP) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 18.2% versus a loss of 61.6%. Over five years, VYGR leads with a -49.9% price change compared with -97.4% for NRXP. Voyager Therapeutics is the larger company by market cap ($117.1 million vs $112.6 million), about 1.0 times the size.
Voyager Therapeutics converts more of its revenue into profit, with a net margin of -296.5% versus -2336.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | VYGR |
|---|---|---|
| Share price | $2.60 | $1.90 |
| Market cap | $112.57M | $117.07M |
| 1-day change | -4.06% | -7.77% |
| YTD return | -4.06% | -51.65% |
| 1-year return | -18.24% | -61.62% |
| 5-year return | -97.37% | -49.87% |
| EPS (TTM) | $-0.58 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.23M | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | $-28.62M | $-119.72M |
| Gross margin | 58.78% | — |
| Operating margin | -1324.41% | -326.56% |
| Net margin | -2336.49% | -296.53% |
| 52-week high | $5.06 | $5.48 |
| 52-week low | $1.62 | $1.89 |
| Distance from 52-week high | -48.57% | -65.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1380.77% | +683.68% |
| Average volume | 860.32K | 578.54K |
| Shares outstanding | 43.30M | 61.62M |
| Employees | 29 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed VYGR by 43.4 percentage points over the past year.
- Voyager Therapeutics is more profitable, keeping -296.5 cents of every revenue dollar as net income versus -2336.5 cents for NRX Pharmaceuticals.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
NRXP vs VYGR FAQ
Which is bigger, NRX Pharmaceuticals or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $117.07M compared with $112.57M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, NRXP or VYGR?
NRXP returned -18.24% over the past 12 months, compared with -61.62% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and Voyager Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for NRX Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Voyager Therapeutics.